Latest News

  • FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder Read More
  • Trading in Alkermes Ordinary Shares Halted Today Read More
  • Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831 Read More
  • Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress Read More


Response to Current Events